The AJMC® Product Approvals and Launches page will cover the latest FDA product approvals, as well as product launches in the United States.
Factor D Inhibitor Danicopan Approved as Add-On Therapy for PNH
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH
FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension
FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
Givinostat Receives Full FDA Approval for Duchenne Muscular Dystrophy
FDA Approves Idorsia's Tryvio for Resistant Hypertension
Agamree Now Commercially Available to Treat Duchenne Muscular Dystrophy
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
FDA Approves Arsa-Cel for Metachromatic Leukodystrophy
Dr Ben Rome Scrutinizes the FDA’s Accelerated Approval Pathway for DMD Treatments, Calls for Policy Reform
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors
Experts Issue Call for Reform to DMD Drug Pricing, Trial Approval Process
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
Dr Joshua Sabari Looks to the Future of Targeted Treatment for NSCLC
Dr Imran Khan Addresses Teclistamab’s Groundbreaking Impact and Ongoing Promise
FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
Frontline Nivolumab Plus Chemotherapy Approved for Unresectable or Metastatic Urothelial Carcinoma
FDA Approves First Over-the-Counter Continuous Glucose Monitor
FDA Approves First 2 Denosumab Biosimilars
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC
Dr Imran Khan Presents a Closer Look at Teclistamab’s Weight-Based Dosing and Patient-Centric Approach
Dr Imran Khan Discusses Teclistamab’s Expanded Indication for RRMM
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
Osimertinib With Chemo Gains FDA Approval for EGFR-Mutated NSCLC
FDA Grants Accelerated Approval to Lifileucel, First Cellular Therapy for Advanced Melanoma